美国德克萨斯大学医学中心(https://sbmi.uth.edu/ccsm/)周小波教授领导的研究团队9月14日在Genome Biology发表最新研究成果,揭示了组蛋白修饰可通过调控细胞周期相关转录因子或通路基因的可变剪切进而参与ESC定向分化的调控。周小波教授为论文的通讯作者,徐云刚助理教授和赵蔚苓副教授为共同第一作者;该校McGovern医学院Scott D. Olson助理教授和 Karthik S. Prabhakara博士为共同作者。
美国德州大学医学中心终身正教授、Dr. Mrs. Carl V. Vartian教授、计算与系统医学研究中心主任。主要从事数据挖掘、机器学习、生物信息学、系统生物学、生物医学成像、再生医学、临床与转化医学信息学、与手术设计与优化等的研究。先后在北大、清华、兰大、华为、Missouri-Colombia大学、Texas AM大学、Harvard大学、Cornell大学、维克森林大学、德州大学医学中心从事大数据,生物医学信息学与影像等的研发工作。
1. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T: Regulation of alternative splicing by histone modifications. Science 2010, 327:996-1000.
2. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T: Epigenetics in Alternative Pre-mRNA Splicing.Cell 2011, 144:16-26.
3. Pauklin S, Vallier L: The Cell-Cycle State of Stem Cells Determines Cell Fate Propensity (vol 155, pg 135, 2013). Cell 2014, 156:1338-1338.
5. Dalton S: Linking the Cell Cycle to Cell Fate Decisions. Trends in Cell Biology 2015, 25:592-600.
6. Foa R, Vitale A, Cuneo A, Mecucci C, Mancini H, Cimino G, Cutinelli F, Saglio G, Torelli G, Quarta G, et al: E2A-PBX1 fusion in adult acute lymphoblastic leukemia (ALL) with t(1;19) translocation: Biologic and clinical features. Blood 2000, 96:189b-189b.
7. Jung JG, Kim TH, Gerry E, Kuan JC, Ayhan A, Davidson B, Shih IM, Wang TL: PBX1, a transcriptional regulator, promotes stemness and chemoresistance in ovarian cancer. Clinical Cancer Research2016, 22.
8. Magnani L, Patten DK, Nguyen VTM, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, et al: The pioneer factor PBX1 is a novel driver of metastatic progression in ER-positive breast cancer. Oncotarget 2015, 6:21878-21891.
9. Feng Y, Li L, Zhang X, Zhang Y, Liang Y, Lv J, Fan Z, Guo J, Hong T, Ji B, et al: Hematopoietic pre-B cell leukemia transcription factor interacting protein is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration, and invasion. Cancer Sci 2015, 106:1313-1322.
10. Thiaville MM, Stoeck A, Chen L, Wu RC, Magnani L, Oidtman J, Shih IM, Lupien M, Wang TL:Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites.Plos One 2012, 7.
11. Park JT, Shih Ie M, Wang TL: Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 2008, 68:8852-8860.
12. Qiu Y, Tomita Y, Zhang B, Nakamichi I, Morii E, Aozasa K: Pre-B-cell leukemia transcription factor 1 regulates expression of valosin-containing protein, a gene involved in cancer growth. Am J Pathol 2007, 170:152-159.
13. Kim SK, Selleri L, Lee JS, Zhang AY, Gu XY, Jacobs Y, Cleary ML: Pbx1 inactivation disrupts pancreas development and in Ipf1-deficient mice promotes diabetes mellitus. Nature Genetics 2002,30:430-435.
14. Koss M, Bolze A, Brendolan A, Saggese M, Capellini TD, Bojilova E, Boisson B, Prall OWJ, Elliott DA, Solloway M, et al: Congenital Asplenia in Mice and Humans with Mutations in a Pbx/Nkx2-5/p15 Module. Developmental Cell 2012, 22:913-926.
摘要:
Background
Understanding the embryonic stem cell (ESC) fate decision between self-renewal and proper differentiation is important for developmental biology and regenerative medicine. Attention has focused on mechanisms involving histone modifications, alternative pre-messenger RNA splicing, and cell-cycle progression. However, their intricate interrelations and joint contributions to ESC fate decision remain unclear.
Results
We analyze the transcriptomes and epigenomes of human ESC and five types of differentiated cells. We identify thousands of alternatively spliced exons and reveal their development and lineage-dependent characterizations. Several histone modifications show dynamic changes in alternatively spliced exons and three are strongly associated with 52.8% of alternative splicing events upon hESC differentiation. The histone modification-associated alternatively spliced genes predominantly function in G2/M phases and ATM/ATR-mediated DNA damage response pathway for cell differentiation, whereas other alternatively spliced genes are enriched in the G1 phase and pathways for self-renewal. These results imply a potential epigenetic mechanism by which some histone modifications contribute to ESC fate decision through the regulation of alternative splicing in specific pathways and cell-cycle genes. Supported by experimental validations and extended datasets from Roadmap/ENCODE projects, we exemplify this mechanism by a cell-cycle-related transcription factor, PBX1, which regulates the pluripotency regulatory network by binding to NANOG. We suggest that the isoform switch from PBX1a to PBX1b links H3K36me3 to hESC fate determination through the PSIP1/SRSF1 adaptor, which results in the exon skipping of PBX1.
Conclusion
We reveal the mechanism by which alternative splicing links histone modifications to stem cell fate decision.
Genome Biology (https://genomebiology.biomedcentral.com/) publishes outstanding research in all areas of biology and biomedicine studied from a genomic and post-genomic perspective.
The current impact factor is 13.214* and the journal is ranked 4th among research journals in the Genetics and Heredity category by Thomson Reuters. Genome Biology is the highest ranked open access journal in the category.